PEPVERAAUTHENTIC HIGH-QUALITY PEPTIDES
SIGN IN
Semaglutide
CUT · III

Semaglutide

The first ascent.

From / per milligram
$45$9.0/mg · 5MG
Sizes available
5mg · 10mg · 15mg · 20mg
Lab certificate (COA)
Supplier-published sample
Compare 1 suppliers ↓View test certificate →

· Research-grade only · Not for human consumption · 21+ ·

What is it

FDA-approved weight-loss and type 2 diabetes therapy (Wegovy / Ozempic). The widest clinical dataset in the class.

Mechanism · GLP-1 receptor agonist. STEP / SUSTAIN Phase 3. FDA approved 2017 / 2021.

Who

Best for. Not for.

Best for

  • The most-validated weight-loss evidence base.
  • Type 2 diabetes (Ozempic 2017).
  • Cardiovascular risk reduction (SELECT 2023. MACE -20%).
  • Weekly subcutaneous injection or the oral Rybelsus option.
  • Broad insurance coverage and lower cost.

Not for

  • Personal or family history of MTC or MEN-2 (FDA boxed warning).
  • History of pancreatitis.
  • Pregnancy, nursing, or planned pregnancy.
  • Type 1 diabetes or elevated DKA risk.
  • Active diabetic retinopathy progression (SUSTAIN-6 signal).
What it does

Mechanism, dose, ramp, risk.

Mechanism
GLP-1 receptor agonist. Long-validated entry (Ozempic / Wegovy).Source · PEPVERA editorial
Target dose
2 mg / week by week 12.Source · PEPVERA editorial
Ramp
16 weeks. Begin at 0.25 mg.Source · PEPVERA editorial
Risks
Nausea, fatigue, anhedonia (mental health advisory).Source · PEPVERA editorial
Alternatives

Compared to its siblings.

★ Currently viewing

Semaglutide

FDA-approved weight-loss and type 2 diabetes therapy (Wegovy / Ozempic). The widest clinical dataset in the class.

Pros

  • · Widest clinical and long-term dataset in the class.
  • · Lower cost and broader insurance coverage than tirzepatide.
  • · FDA-approved with stable supply, unlike retatrutide.
  • · Stronger efficacy than liraglutide (~15% vs ~8%) on a weekly schedule.

Cons

  • · Lower fat-loss potency than tirzepatide (~15% vs ~21%).
  • · Weaker lean-mass preservation than tirzepatide (SURMOUNT-5).
  • · Lower Phase 2 weight loss than retatrutide (~15% vs ~24%).
  • · Shorter safety record than liraglutide and no pediatric approval.

Tirzepatide

GLP-1 + GIP. Deeper fat loss with less nausea.

Pros

  • · ~21% Mean weight loss vs ~15% for semaglutide.
  • · Better lean-mass preservation (SURMOUNT-5).

Cons

  • · Higher cost.
  • · Shorter long-term dataset (FDA 2022).

See Tirzepatide →

Retatrutide

Triple receptor (+glucagon). The deepest Phase 2 fat loss to date.

Pros

  • · ~24% Mean weight loss in Phase 2.
  • · Glucagon arm raises energy expenditure.

Cons

  • · Still Phase 2. No FDA approval.

See Retatrutide →

Liraglutide

First-gen daily injection. The longest safety history and a pediatric label.

Pros

  • · Longest safety record in the class.
  • · FDA pediatric (12+) approval (Saxenda).

Cons

  • · Daily injection burden.
  • · About 8% mean weight loss. Weaker than semaglutide.

See Liraglutide →

How we verify

COA per supplier

Published, in-house, or shipment-time

Each supplier declares its own HPLC floor and COA policy. The per-supplier verifier appears on the certificate page; refund and shipping terms vary by supplier and are shown on the supplier listing.

→ How we verify suppliers→ Refund policy
Fat lossMetabolicappetite-suppressantGLP-1Popularmental-health-advisoryresearch-only
Suppliers

Compare 4 suppliers

SupplierPriceCOAShips
Royal PeptidesUS$45$9.00/mg · 5mgSample COA published3 days
Royal PeptidesUS$75$7.50/mg · 10mgSample COA published3 days
Royal PeptidesUS$110$7.33/mg · 15mgSample COA published3 daysOut of stock
Royal PeptidesUS$155$7.75/mg · 20mgSample COA published3 days
❄ COLD-CHAIN · 5–9 DAYS

Direct from foundry. Slower than domestic resellers; consistency is the trade. Insulated packaging, tracked from departure to doorstep. Replacement issued on damage.

Before you begin

Risk

Nausea, fatigue, anhedonia (mental health advisory). These pass with discipline. They do not pass with bravado.

Source · PEPVERA editorial

Discipline

16 weeks. Begin at 0.25 mg.

Source · PEPVERA editorial

Wellness

Hydrate. Eat protein. Sleep eight. Hold a dose for at least two weeks before ascending.

Anti-patterns

  • · Do not pair with stimulants late in the day.
  • · Do not break the cycle without a planned taper.
  • · Do not exceed the dose to chase a deeper sleep response.

Crisis

If the ramp triggers severe anxiety, anhedonia, or persistent gastrointestinal disturbance, stop. Resume after two weeks at half the prior dose. The discipline is the slow climb.

Dosing protocol

Week 1–2

0.25 mg / wk

Baseline ramp

Week 3–4

0.5 mg / wk

Hold, observe

Week 5–8

1.0–2.0 mg / wk

Ascend

Week 9–12

2 mg / week by week 12.

Terminus

Reconstitution

Draw 20 units.

0.5 mg = 0.20 mL at 2.50 mg/mL. 10.0 doses per vial.

cut · III · Royal Peptides

Semaglutide · 5mg